Impact ledger
Alnylam Pharmaceuticals, Inc. (ALNY): the developments shaping its investment case
Follow the evidence affecting Alnylam Pharmaceuticals, Inc.. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.
Research Alnylam Pharmaceuticals, Inc. · $399/mo
Test assumptions, examine opportunities, and save your research.
Material developments
2026-08-26
Multiple System Atrophy Drug Pipeline Expands to 24 Clinical Candidates Across 22 Firms
Channel: Potential for increased competition or partnership opportunities in RNAi-based therapies for neurological disorders.
watch· 3-12m
2026-09-24 · 3 reports
Ionis Reports Positive Phase III Endpoints in ALS and Kidney Disease
Channel: Indirect competitive pressure in the RNAi therapeutic space. Ionis's success reinforces the viability of antisense oligonucleotide (ASO) technology, which is related to Alnylam's RNAi platform, but also introduces potential competition in specific disease areas.
watch· 3-12m
2026-09-25 · 4 reports
ADARx Pharmaceuticals prices upsized $446.3M initial public offering at $17 per share
Channel: Increased competition in the siRNA therapeutic space, potential for new comparative data.
mixed· 3-12m
Event impact log
13 events mapped to ALNY since 2026-08-26. Evidence through 2026-09-25.
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-09-25 | ADARx Pharmaceuticals prices upsized $446.3M initial public offering at $17 per share | Increased competition in the siRNA therapeutic space, potential for new comparative data. | mixed | 3-12m | 0.20 |
| 2026-09-25 | ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17 per Share | Increased competition or validation of the siRNA therapeutic platform. | watch | 1-3m | 0.20 |
| 2026-09-25 | ADARx Pharmaceuticals Prices Upsized $446.3M Initial Public Offering at $17 | Similar to Moderna, Alnylam is a leader in RNA interference (RNAi) therapeutics. ADARx's successful IPO in the RNA-targeting space could signal increased investor confidence and capital availability for companies developing similar technologies. | Bullish | 1-3m | 0.40 |
| 2026-09-25 | ADARx Pharmaceuticals prices upsized $446.3M IPO at $17 per share | Increased investor attention and potential competitive landscape shifts within the siRNA therapeutic space. | watch | 1-3m | 0.30 |
| 2026-09-24 | Ionis Reports Positive Phase III Endpoints in ALS and Kidney Disease | Indirect competitive pressure in the RNAi therapeutic space. Ionis's success reinforces the viability of antisense oligonucleotide (ASO) technology, which is related to Alnylam's RNAi platform, but also introduces potential competition in specific disease areas. | watch | 3-12m | 0.20 |
| 2026-09-24 | Ionis reports positive Phase III trial results for partnered drugs in ALS and kidney disease | Ionis's success in RNA-targeted therapies could validate or intensify competition in the broader RNA therapeutics space, potentially affecting investor sentiment or R&D focus. | watch | 3-12m | 0.30 |
| 2026-09-24 | Vertex Reports Phase IIb Data for Inaxaplin with 42.7% Proteinuria Drop in AMKD | Indirect competitive pressure or market sentiment shift in the rare kidney disease space. Potential for increased investor scrutiny on competing pipeline assets. | watch | 3-12m | 0.30 |
| 2026-09-24 | Ionis Announces Positive Phase III Trials for ALS and IgA Nephropathy Therapies | Indirect sector sentiment and validation of RNA-targeted therapies. | watch | 3-12m | 0.20 |
| 2026-09-24 | Ionis Announces Positive Phase III Results for Partnered FUS-ALS and IgAN Programs | Positive sentiment spillover for RNA-targeted therapies. Ionis's success validates the platform, potentially benefiting other companies in the space. | Bullish | 1-3m | 0.40 |
| 2026-09-24 | Vertex Reports Positive Phase IIb Kidney Disease Data for Inaxaplin | Indirect competitive pressure in the rare disease and genetic kidney disease space, potentially influencing investor sentiment or R&D focus. | watch | 3-12m | 0.20 |
| 2026-09-23 | Roche to Acquire Ionis Pharmaceuticals, Inc. | Increased M&A activity and valuation benchmarks for RNA-targeted therapies, a core technology for both Ionis and Alnylam. | watch | 3-12m | 0.30 |
| 2026-09-21 | Ionis Plunges Over 40% YTD on Late-Stage Setbacks Despite Bullish Targets | Sector-wide sentiment impact on companies utilizing oligonucleotide-based therapies (RNAi, ASO). | watch | 1-3m | 0.20 |
| 2026-08-26 | Multiple System Atrophy Drug Pipeline Expands to 24 Clinical Candidates Across 22 Firms | Potential for increased competition or partnership opportunities in RNAi-based therapies for neurological disorders. | watch | 3-12m | 0.50 |
Continue this research
Build your Alnylam Pharmaceuticals, Inc. investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.
This ledger is regenerated from Market Ontology's public event pipeline. View the ALNY entity page →